390 related articles for article (PubMed ID: 34623572)
1. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
[TBL] [Abstract][Full Text] [Related]
4. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Lorusso D; Mouret-Reynier MA; Harter P; Cropet C; Caballero C; Wolfrum-Ristau P; Satoh T; Vergote I; Parma G; Nøttrup TJ; Lebreton C; Fasching PA; Pisano C; Manso L; Bourgeois H; Runnebaum I; Zamagni C; Hardy-Bessard AC; Schnelzer A; Fabbro M; Schmalfeldt B; Berton D; Belau A; Lotz JP; Gropp-Meier M; Gladieff L; Lück HJ; Abadie-Lacourtoisie S; Pujade-Lauraine E; Ray-Coquard I
Int J Gynecol Cancer; 2024 Apr; 34(4):550-558. PubMed ID: 38129136
[TBL] [Abstract][Full Text] [Related]
5. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
7. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract][Full Text] [Related]
8. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
9. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
[TBL] [Abstract][Full Text] [Related]
10. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
[TBL] [Abstract][Full Text] [Related]
12. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Poveda A; Lheureux S; Colombo N; Cibula D; Lindemann K; Weberpals J; Bjurberg M; Oaknin A; Sikorska M; González-Martín A; Madry R; Pérez MJR; Ledermann J; Davidson R; Blakeley C; Bennett J; Barnicle A; Škof E
Gynecol Oncol; 2022 Mar; 164(3):498-504. PubMed ID: 35063276
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
14. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
15. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
[TBL] [Abstract][Full Text] [Related]
16. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
Zhu Y; Liu K; Cao H; Zhu H
J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
[TBL] [Abstract][Full Text] [Related]
18. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
19. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
Zhu Y; Yang Q; Liu K; Cao H; Zhu H
J Gynecol Oncol; 2024 Jan; 35(1):e2. PubMed ID: 37477106
[TBL] [Abstract][Full Text] [Related]
20. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]